Adjuvant gemcitabine after resection of pancreatic cancer without significant difference in overall survival: a retrospective cohort study.
adjuvant chemotherapy
ductal adenocarcinoma
gemcitabine
guidelines
pancreatic carcinoma
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
19
01
2023
accepted:
10
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
International guidelines recommend adjuvant chemotherapy after resection of pancreatic adenocarcinoma. The administration of gemcitabine has become part of the interdisciplinary treatment concept. The authors aim to prove whether the benefit in overall survival (OS) reported in randomized controlled trials (RCTs) could be reached also for patients treated in their department. The authors retrospectively analyzed the OS of all patients who underwent pancreatic resection at their clinic because of ductal adenocarcinoma between January 2013 and December 2020 in dependence on adjuvant treatment with gemcitabine. Overall 133 pancreatic resections were performed between 2013 and 2020 due to malignant pancreatic pathology. Seventy-four patients had ductal adenocarcinoma. Forty patients received adjuvant gemcitabine chemotherapy postoperatively, 18 patients underwent only surgical resection, and 16 patients received other chemotherapy regimens. The authors compared the group receiving adjuvant gemcitabine ( OS with and without adjuvant chemotherapy with gemcitabine was comparable to the results of those RCTs which serve as the basis of guideline recommendations. However, the analyzed patient cohort did not profit significantly from the adjuvant treatment.
Identifiants
pubmed: 37427179
doi: 10.1097/MS9.0000000000000854
pii: AMSU-D-23-00144
pmc: PMC10328665
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3284-3290Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Br J Cancer. 2009 Sep 15;101(6):908-15
pubmed: 19690548
Z Gastroenterol. 2013 Dec;51(12):1395-440
pubmed: 24338757
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
N Engl J Med. 2004 Mar 18;350(12):1200-10
pubmed: 15028824
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Lancet. 2016 Jul 16;388(10041):248-57
pubmed: 27265347
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
Radiat Oncol. 2011 Sep 28;6:126
pubmed: 21951377
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):236-244
pubmed: 28603091
Arch Intern Med. 2002 Aug 12-26;162(15):1682-8
pubmed: 12153370
Chest. 2020 Jul;158(1S):S79-S87
pubmed: 32658656
JAMA. 2010 Sep 8;304(10):1073-81
pubmed: 20823433
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Drug Des Devel Ther. 2018 Mar 07;12:475-480
pubmed: 29563772
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Medicina (Kaunas). 2018 Jul 11;54(3):
pubmed: 30344279
Pancreas. 2004 Apr;28(3):219-30
pubmed: 15084961
Clin Transl Oncol. 2016 Dec;18(12):1172-1178
pubmed: 27896637
Int J Surg. 2021 Dec;96:106165
pubmed: 34774726
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
JAMA Surg. 2018 Dec 1;153(12):e183617
pubmed: 30285076
Presse Med. 2019 Mar;48(3 Pt 2):e159-e174
pubmed: 30879894
Int J Risk Saf Med. 2023;34(1):29-40
pubmed: 34897105
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417